Mutations of KRAS, NRAS, BRAF, and other components of the cascade are well-known in several cancers, including gastrointestinal, pulmonary, and skin malignancies, and represent the substrate for the targeted therapies currently in use [69,70]. Here, BRAF is linked to cancer.